Evaluation of bacterial uptake, antibacterial efficacy against Escherichia coli , and cytotoxic effects of moxifloxacin-loaded solid lipid nanoparticles
Merve Eylul Kiymaci
University of Health Sciences Turkey, Gülhane Faculty of Pharmacy, Department of Pharmaceutical MicrobiologyAnkara, Turkey
Profilo OrcidCerca questo autore su
, , , , , , e 30 dic 2022
INFORMAZIONI SU QUESTO ARTICOLO
Categoria dell'articolo: Original article
Pubblicato online: 30 dic 2022
Pagine: 260 - 269
Ricevuto: 01 lug 2022
Accettato: 01 nov 2022
DOI: https://doi.org/10.2478/aiht-2022-73-3667
Parole chiave
© 2022 Merve Eylul Kiymaci, Gizem Ruya Topal, Ozgur Esim, Merve Bacanli, Cansel Kose Ozkan, Onur Erdem, Ayhan Savaser, Yalcin Ozkan, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Figure 1
Figure 2
Figure 3
Figure 4
Cytotoxic effects of MOX, MOX-free, and MOX-loaded LNPs in RAW 264_7 cells
| RAW 264.7 cell viability (%) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24 h | 48 h | 72 h | ||||||||||
| 0.010 µg/mL | 0.025 µg/mL | 0.05 µg/mL | 0.1 µg/mL | 0.010 µg/mL | 0.025 µg/mL | 0.05 µg/mL | 0.1 µg/mL | 0.010 µg/mL | 0.025 µg/mL | 0.05 µg/mL | 0.1 µg/mL | |
| 88.65±0.09 | 69.05±0.35 | 56.48±0.01 | 89.42±0.02 | 73.98±0.33 | 59.43±0.02 | 86.62±0.23 | 83.49±0.08 | 54.58±0.02 | ||||
| 81.56±0.26 | 75.43±0.29 | 75.92±0.23 | 74.55±0.23 | 94.62±0.02 | 81.95±0.11 | 71.44±0.03 | 58.43±0.06 | 92.13±0.08 | 91.46±0.34 | 89.06±0.28 | 73.70±0.22 | |
| 95.30±0.08 | 68.91±0.12 | 62.78±0.25 | 95.75±0.29 | 91.22±0.05 | 85.44±0.06 | 64.09±0.03 | 87.12±0.27 | 82.65±0.09 | 73.35±0.11 | 69.72±0.17 | ||
| 93.14±0.08 | 80.42±0.19 | 66.66±0.46 | 62.10±0.21 | 88.73±0.06 | 77.09±0.12 | 63.16±0.12 | 56.05±0.04 | 92.13±0.08 | 91.46±0.34 | 89.06±0.28 | 73.71±0.22 | |
| 90.98±0.30 | 86.81±0.12 | 64.91±0.09 | 60.60±0.31 | 96.51±0.22 | 94.42±0.12 | 80.82±0.08 | 68.49±0.22 | 96.02±0.33 | 87.31±0.27 | 69.95±0.09 | 55.88±0.06 | |
| 80.46±0.09 | 81.65±0.18 | 85.84±0.26 | 81.47±0.09 | 88.72±0.09 | 72.27±0.04 | 62.23±0.02 | 51.10±0.15 | 85.24±0.09 | 76.56±0.30 | 73.78±0.09 | 56.03±0.32 | |
| 89.19±0.13 | 78.73±0.17 | 70.83±0.33 | 53.27±0.04 | 92.75±0.13 | 82.93±0.04 | 63.82±0.09 | 54.44±0.05 | 89.70±0.09 | 80.44±0.08 | 63.51±0.35 | 54.76±0.20 | |
| 78.43±0.31 | 65.99±0.05 | 56.58±0.29 | 50.72±0.04 | 76.23±0.27 | 59.40±0.03 | 53.59±0.06 | 53.05±0.08 | 94.10±0.27 | 79.09±0.03 | 73.90±0.06 | 51.68±0.17 | |
| 85.54±0.07 | 60.58±0.10 | 56.67±0.26 | 50.07±0.16 | 83.62±0.06 | 62.94±0.12 | 54.81±0.05 | 52.27±0.04 | 91.99±0.42 | 82.25±0.12 | 74.99±0.05 | 54.11±0.09 | |
Lipid nanoparticle properties
| SLN1 | 181.6±1.27 | 0.25±0.02 | -14.6±0.32 | 68.61±0.20 |
| SLN2 | 201.8±1.65 | 0.29±0.02 | -17.5±0.14 | 74.53±0.34 |
| NLC1 | 176.8±1.90 | 0.57±0.23 | -11.6±0.61 | 77.82±0.21 |
| NLC2 | 132.4±1.62 | 0.51±0.53 | -6.3±0.38 | 77.17±0.21 |
Stability of lipid nanoparticles stored for one month at +4 °C
| Type of LNPs | Baseline value | After one month storage | Baseline value | After one month storage | Baseline value | After one month storage |
|---|---|---|---|---|---|---|
| SLN1 | 181.6±1.27 | 186.1±2.89 | 0.25±0.02 | 0.36±0.25 | -14.6±0.32 | |
| SLN2 | 201.8±1.65 | 200.5±3.56 | 0.29±0.02 | 0.39±0.12 | -17.5±0.14 | |
| NLC1 | 176.8±1.90 | 180.3±1.64 | 0.57±0.23 | 0.60±0.46 | -11.6±0.61 | -8.30±0.78 |
| NLC2 | 132.4±1.62 | 135.2±3.98 | 0.51±0.53 | 0.65±0.22 | -6.3±0.38 | -5.62±0.96 |
Composition of lipid nanoparticles
| SLN1 | 150 mg | - | - | 100 mg | - | - |
| SLN2 | 150 mg | - | - | - | 100 mg | - |
| NLC1 | 110 mg | 40 mg | 10 mg | - | 100 mg | 10 mg |
| NLC2 | 110 mg | 40 mg | - | - | 100 mg | 10 mg |
Antibacterial activity of MOX-loaded SLNs and NLCs
| Standard MOX solution for SLNs * (0.68 mg) | 33±0.07 | 0.041 |
| SLN1 | 0.020 | |
| SLN2 | 32±0.11 | 0.041 |
| Standard MOX solution for NLCs** (0.78 mg) | 35±0.08 | 0.023 |
| NLC1 | 36±0.12 | 0.023 |
| NLC2 | 35±0.05 | 0.023 |